Small molecule glucagon receptor antagonists: a patent review (2011 – 2014)

Bibliography

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
   PubMed Web of Science ®Google Scholar
• Kaiser D, Oetjen E. Something old, something new and something very old: drugs for treating type 2 diabetes. Br J Pharmacol 2014;171(12):2940-50
   Google Scholar
• Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378(9786):182-97
   PubMed Web of Science ®Google Scholar
• Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006;12(14):1731-50
   Google Scholar
• Johnson DG, Goebel CU, Hruby VJ, et al. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982;215(4536):1115-16
   PubMedGoogle Scholar
• Gysin B, Trivedi D, Johnson DG, Hruby VJ. Design and synthesis of glucagon partial agonists and antagonists. Biochemistry 1986;25(25):8278-84
   Google Scholar
• Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003;100(3):1438-43
   PubMed Web of Science ®Google Scholar
• Sorensen H, Winzell MS, Brand CL, et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 2006;55(12):3463-9
   Google Scholar
• Conarello SL, Jiang G, Mu J, et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007;50(1):142-50
   PubMed Web of Science ®Google Scholar
• Lee Y, Wang M-Y, Du XQ, et al. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011;60(2):391-7
   PubMed Web of Science ®Google Scholar
• Vuguin PM, Charron MJ. Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes Metab 2011;13(Suppl 1):144-50
   PubMed Web of Science ®Google Scholar
• Sorensen H, Brand CL, Neschen S, et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006;55(10):2843-8
   Google Scholar
• Brand CL, Rolin B, Jorgensen PN, et al. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 1994;37(10):985-93
   PubMed Web of Science ®Google Scholar
• Liang Y, Osborne MC, Monia BP, et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004;53(2):410-17
   PubMedGoogle Scholar
• Sloop KW, Cao JX, Siesky AM, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004;113(11):1571-81
   PubMed Web of Science ®Google Scholar
• Collins JL, Dambek PJ, Goldstein SW, Faraci WS. CP-99,711: a nonpeptide glucagon receptor antagonist. Bioorg Med Chem Lett 1992;2(9):915-18
   Google Scholar
• Madsen P, Brand CL, Holst JJ, Knudsen B. Advances in non-peptide glucagon receptor antagonists. Curr Pharm Des 1999;5(9):683-91
   Google Scholar
• DeMong DE, Miller MW. Glucagon receptor antagonists in development. In: Jones RM, editor. New therapeutic strategies for type 2 diabetes: small molecule approaches. The Royal Society of Chemistry; Cambridge, UK: 2012. p. 429-63
   Google Scholar
• DeMong DE, Miller MW, Lachowicz JE. Glucagon receptor antagonists for type II diabetes. Annu Rep Med Chem 2008;43:119-37
   Google Scholar
• Ling A. Small-molecule glucagon receptor antagonists. Drugs Future 2002;27(10):987-93
   Google Scholar
• Ling AL, Wasserman JI. Approaches to glucagon receptor antagonists. Expert Opin Ther Pat 2003;13(1):15-22
   Google Scholar
• Kurukulasuriya R, Link J. Progress towards glucagon receptor antagonist therapy for type 2 diabetes. Expert Opin Ther Pat 2005;15(12):1739-49
   Web of Science ®Google Scholar
• Shen DM, Lin S, Parmee ER. A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010). Expert Opin Ther Pat 2011;21(8):1211-40
   Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma Co., Ltd. Preparation of 3-substituted-2-furancarboxylic acid hydrazide derivatives as glucagon receptor antagonists. WO2011007722; 2011
   Google Scholar
• Dainippon Sumitomo Pharma Co., Ltd. Preparation of 3-(4-aminophenyl)-2-furancarboxylic acid hydrazide derivatives as glucagon receptor antagonists and pharmaceutically acceptable salts thereof. WO2010131669; 2010
   Google Scholar
• Hasegawa F, Niidome K, Migihashi C, et al. Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists. Bioorg Med Chem Lett 2014;24(17):4266-70
   Google Scholar
• Lau J, Behrens C, Sidelmann UG, et al. New beta-alanine derivatives are orally available glucagon receptor antagonists. J Med Chem 2007;50(1):113-28
   Google Scholar
• Janssen Pharmaceutica NV. Preparation of biphenylcarboxamidopropanoic acid derivatives for use as glucagon receptor antagonists. WO2012162409; 2012
   Google Scholar
• Janssen Pharmaceutica NV. Preparation of picolinamido propanoic acid derivatives useful as glucagon receptor antagonists. WO2012162407; 2012
   Google Scholar
• Janssen Pharmaceutica NV. Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists. US8748624; 2014
   Google Scholar
• Madsen P, Ling A, Plewe M, et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem 2002;45(26):5755-75
   Google Scholar
• Lau J, Behrens C, Sidelmann UG, et al. New beta-alanine derivatives are orally available glucagon receptor antagonists. J Med Chem 2007;50(1):113-28
   Google Scholar
• Pfizer, Inc. Preparation of heterocycle-containing compounds as glucagon receptor modulators for therapy. WO2012085745; 2012
   Google Scholar
• Pfizer, Inc. Glucagon receptor modulators. US8809342; 2014
   Google Scholar
• Pfizer, Inc. Preparation of 3-[4-(heterocyclyl-substituted)-benzamido]propanoic acids as glucagon receptor modulators. US20120202834; 2012
   Google Scholar
• Guzman-Perez A, Pfefferkorn JA, Lee EC, et al. The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 2013;23(10):3051-8
   Google Scholar
• Pfizer, Inc. Glucagon receptor modulators. US8859591; 2014
   Google Scholar
• Pfizer, Inc. Glucagon receptor modulators. US8507533; 2013
   Google Scholar
• Pfizer, Inc. Preparation of quinolinyl glucagon receptor modulators. WO2013014569; 2013
   Google Scholar
• Schering Corp. Pyrrolidines as glucagon receptor antagonists and their preparation and use for the treatment and prevention of type 2 diabetes and related diseases. WO2011037815; 2011
   Google Scholar
• Merck & Co., Inc. Processes for preparation of a substituted pyrazole useful as a glucagon receptor antagonist. WO2007015999; 2007
   Google Scholar
• Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use. US8735604; 2014
   Google Scholar
• Schering Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists and their preparation and use for the treatment and prevention of type 2 diabetes and related conditions. WO2011119541; 2011
   Google Scholar
• Schering Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists and their preparation and use for treatment and prevention of type 2 diabetes and related conditions. WO2011119559; 2011
   Google Scholar
• Schering Corp. Preparation of spiro-imidazolone derivatives as glucagon receptor antagonists for treatment of diabetes. WO2010039789; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Preparation of heterocyclic compounds as glucagon antagonists. WO2011027849; 2011
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Preparation of (heterocyclylmethyl)amine compounds as glucagon receptor antagonists. WO2009110520; 2009
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Preparation of aromatic ring compounds as glucagon antagonists. WO2013147026; 2013
   Google Scholar
• Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001;44(11):2018-24
   PubMedGoogle Scholar
• Xiong Y, Guo J, Candelore MR, et al. Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-beta-alanine (MK-0893) for the treatment of type II diabetes. J Med Chem 2012;55(13):6137-48
   PubMed Web of Science ®Google Scholar
• Engel SS, Reitman ML, Xu L, et al. Glycemic and lipid effects of the short-acting glucagon receptor antagonist MK-3577 in patients with type 2 diabetes. Diabetes 2012;61(Suppl 1):A266
   Google Scholar
• Peng JZ, Denney WS, Musser BJ, et al. A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. AAPS J 2014;16(6):1259-70
   Google Scholar
• Chung JYL, Steinhuebel D, Krska SW, et al. Asymmetric synthesis of a glucagon receptor antagonist via friedel-crafts alkylation of indole with chiral alpha-phenyl benzyl cation. Org Process Res Dev 2012;16(11):1832-45
   Google Scholar
• Merck Sharp & Dohme Corp. Preparation and crystalline polymorphic forms of an antidiabetic indole beta-alanine derivative. WO2010080971; 2010
   Google Scholar
• Merck pipeline as of November 4, 2009. Available from: www.merck.com/research/pipeline/Merck%20October%202009%20Combined%20Pipeline.pdf [Last accessed 7 January 2015]
   Google Scholar
• Merck pipeline as of February 12, 2010. Available from: www.merck.com/research/pipeline/pipeline-feb-2010.pdf [Last accessed 7 January 2015]
   Google Scholar
• Merck pipeline as of April 30, 2010. Available from: www.merck.com/research/pipeline/pipeline-may-2010.pdf [Last accessed 7 January 2015]
   Google Scholar
• Merck pipeline as of July 30, 2010. Available from: www.merck.com/research/pipeline/pipeline-july-2010.pdf [Last accessed 7 January 2015]
   Google Scholar
• Kazda C, Headlee S, Ding Y, et al. The glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with T2DM: a 24 week phase 2 study. Diabetes 2013;62(Suppl 1):A29
   Google Scholar
• DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr 2014;27(2):100-12
   PubMedGoogle Scholar
• Lilly clinical development pipeline as of January 23, 2015. Available from: http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/index.html#PhaseII [Last accessed 13 March 2015]
   Google Scholar
• Pfizer pipeline as of November 6, 2014. Available from: www.pfizer.com/research/science_and_technology/product_pipeline [Last accessed 7 January 2015]
   Google Scholar
• Pfizer pipeline as of February 27, 2015. Available from: http://www.pfizer.com/research/science_and_technology/product_pipeline [Last accessed 13 March 2015]
   Google Scholar
• Pfizer phase 2 clinical trial. Available from: https://clinicaltrials.gov/ct2/show/NCT02175121?term=PF-06291874&rank=3 [Last accessed 13 March 2015]
   Google Scholar
• Ligand diabetes portfolio. Available from: www.ligand.com/diabetes-portfolio [Last accessed 7 January 2015]
   Google Scholar
• Ligand single dose clinical trial. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01919684&Search=Search [Last accessed 7 January 2015]
   Google Scholar
• Vajda EG, Plotkin DJ, Logan D, et al. Pharmacokinetics of the glucagon receptor antagonist LGD-6972. Diabetes 2014;63(Suppl 1):A290
   Google Scholar
• Ligand phase 1 escalating dose. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02250222&Search=Search [Last accessed 7 January 2015]
   Google Scholar
• Ligand - Metabasis merger press release. Available from: investor.ligand.com/Investors/News-and-Events/Press-Releases/Press-Release-Details/2009/Ligand-to-Acquire-Metabasis-for-Cash-and-Contingent-Value-Rights/default.aspx [Last accessed 7 January 2015]
   Google Scholar
• Isis description of GCGRRx. Available from: www.isispharm.com/Pipeline/Therapeutic-Areas/Metabolic-Disease.htm#ISIS-GCGR [Last accessed 7 January 2015]
   Google Scholar
• Isis Pharmaceuticals pipeline. Available from: www.isispharm.com/Pipeline/index.htm [Last accessed 7 January 2015]
   Google Scholar
• Isis press release June 16, 2014. Available from: ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1939938 [Last accessed 7 January 2015]
   Google Scholar
• Mu J, Qureshi SA, Brady EJ, et al. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS ONE 2012;7(11):e49572
   Google Scholar
• Han S, Akiyama TE, Previs SF, et al. Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice. J Lipid Res 2013;54(10):2615-22
   Google Scholar
• Siu FY, He M, de Graaf C, et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 2013;499(7459):444-9
   PubMed Web of Science ®Google Scholar
• Grover S, Dhanjal JK, Goyal S, et al. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus. BMC Bioinformatics 2014;15(Suppl 16):S13
   Google Scholar